{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:34:51Z","timestamp":1760060091584,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["RO1 NS08372"],"award-info":[{"award-number":["RO1 NS08372"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Background: Cerebrotendinous Xanthomatosis (CTX) is a rare, inherited metabolic disease caused by pathogenic variants in CYP27A1. The clinical presentation of this progressive disease includes cognitive deficits, ataxia, peripheral neuropathy, and pyramidal signs, as well as bilateral cataracts and tendon xanthomas. In some cases, CTX also includes parkinsonism. The goals of this study are to develop a data source that provides improved characterization and awareness of parkinsonism in CTX. Methods: We conducted a systematic review of the literature according to PRISMA guidelines to identify all published individuals diagnosed with CTX and parkinsonism. Clinical signs, imaging findings and treatment response to both chenodeoxycholic acid and dopaminergic medications were examined for 72 subjects. Results: The average age of onset of parkinsonism in these CTX patients was 42 years, illustrating the early onset nature of parkinsonism in CTX. Functional dopaminergic imaging revealed the loss of presynaptic dopaminergic neurons in the substantia nigra which points to neurodegeneration of the dopaminergic system as the underlying pathophysiology for parkinsonism in CTX. Brain MRI showed abnormalities in the basal ganglia in 38% of subjects. MRI also showed abnormalities in the cerebellum in 88% of subjects which is typical for CTX and can be utilized to distinguish subjects with CTX and parkinsonism from individuals with other forms of atypical parkinsonism. Dopaminergic medication mitigated parkinsonism signs in most individuals with CTX. Conclusion: CTX is a neurometabolic disease that can result in levodopa-responsive parkinsonism that should be included in the differential for atypical parkinsonism.<\/jats:p>","DOI":"10.3390\/neurolint17080117","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:27Z","timestamp":1753891767000},"page":"117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic Review of Parkinsonism in Cerebrotendinous Xanthomatosis"],"prefix":"10.3390","volume":"17","author":[{"given":"Jennifer","family":"Hanson","sequence":"first","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5581-5301","authenticated-orcid":false,"given":"Penelope E.","family":"Bonnen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1016\/S0021-9258(20)89518-0","article-title":"Mutations in the Bile Acid Biosynthetic Enzyme Sterol 27-Hydroxylase Underlie Cerebrotendinous Xanthomatosis","volume":"266","author":"Cali","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_2","unstructured":"Federico, A., Dotti, M.T., and Gallus, G.N. (2025, July 21). Cerebrotendinous Xanthomatosis; 2016\/04\/14 ed; GeneReviews. Available online: https:\/\/cocukmetabolizma.com\/wp-content\/uploads\/2020\/08\/cerebrotendinous-xanthomatosis.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10545-013-9674-3","article-title":"A Suspicion Index for Early Diagnosis and Treatment of Cerebrotendinous Xanthomatosis","volume":"37","author":"Mignarri","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1468-1331.2011.03439.x","article-title":"Cerebrotendinous Xanthomatosis in Spain: Clinical, Prognostic, and Genetic Survey","volume":"18","author":"Lorenzo","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/08830738030180091001","article-title":"Cerebrotendinous Xanthomatosis: Clinical Manifestations, Diagnostic Criteria, Pathogenesis, and Therapy","volume":"18","author":"Federico","year":"2003","journal-title":"J. Child Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s10038-017-0389-4","article-title":"Nationwide Survey on Cerebrotendinous Xanthomatosis in Japan","volume":"63","author":"Sekijima","year":"2018","journal-title":"J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1542\/peds.2008-0192","article-title":"Chronic Diarrhea and Juvenile Cataracts: Think Cerebrotendinous Xanthomatosis and Treat","volume":"123","author":"Berginer","year":"2009","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1212\/WNL.0000000000006731","article-title":"Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis Depends on Age at Treatment Start","volume":"92","author":"Stelten","year":"2019","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/WNF.0b013e318288076a","article-title":"Neurological Outcome in Cerebrotendinous Xanthomatosis Treated with Chenodeoxycholic Acid: Early Versus Late Diagnosis","volume":"36","author":"Yahalom","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Limphaibool, N., Iwanowski, P., Holstad, M.J.V., and Perkowska, K. (2018). Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00857"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40734-017-0054-2","article-title":"Parkinson Disease in Gaucher Disease","volume":"4","author":"Espay","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10545-018-0152-9","article-title":"Natural History of Neurological Abnormalities in Cerebrotendinous Xanthomatosis","volume":"41","author":"Wong","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mus.21905","article-title":"Neurophysiological Study in Cerebrotendinous Xanthomatosis","volume":"43","author":"Pilo","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_14","first-page":"397","article-title":"Usefulness of Cholestanol Levels in the Diagnosis and Follow-up of Patients with Cerebrotendinous Xanthomatosis","volume":"26","author":"Sobrido","year":"2011","journal-title":"Neurologia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108493","DOI":"10.1016\/j.ymgme.2024.108493","article-title":"Clinical, Biochemical, and Molecular Insights into Cerebrotendinous Xanthomatosis: A Nationwide Study of 100 Turkish Individuals","volume":"142","author":"Zubarioglu","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e165841","DOI":"10.1172\/jci.insight.165841","article-title":"Cholestanol Accelerates Alpha-Synuclein Aggregation and Spreading by Activating Asparagine Endopeptidase","volume":"8","author":"Yu","year":"2023","journal-title":"JCI Insight"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/head.12246","article-title":"The Care Guidelines: Consensus-Based Clinical Case Reporting Guideline Development","volume":"53","author":"Gagnier","year":"2013","journal-title":"Headache"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Aromataris, E., and Munn, Z. (2020). Chapter 7: Systematic Reviews of Etiology and Risk. JBI Manual for Evidence, Synthesis, JBI. Available online: https:\/\/Synthesismanual.Jbi.Global.","DOI":"10.46658\/JBIRM-17-01"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mds.22979","article-title":"Cerebrotendinous Xanthomatosis Patients with and without Parkinsonism: Clinical Characteristics and Neuroimaging Findings","volume":"25","author":"Su","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp.67.2.195","article-title":"Mutations Producing Premature Termination of Translation and an Amino Acid Substitution in the Sterol 27-Hydroxylase Gene Cause Cerebrotendinous Xanthomatosis Associated with Parkinsonism","volume":"67","author":"Wakamatsu","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.parkreldis.2011.04.006","article-title":"Botulinum Toxin-Responsive Oromandibular Dystonia in Cerebrotendinous Xanthomatosis","volume":"17","author":"Posada","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13760-012-0064-7","article-title":"Cerebrotendinous Xanthomatosis Presenting with Asymmetric Parkinsonism: A Case with I-123-Fp-Cit Spect Imaging","volume":"112","author":"Schotsmans","year":"2012","journal-title":"Acta Neurol. Belg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2011.06.004","article-title":"Parkinsonism as Neurological Presentation of Late-Onset Cerebrotendinous Xanthomatosis","volume":"18","author":"Mignarri","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/mds.25229","article-title":"Atypical Parkinsonism and Cerebrotendinous Xanthomatosis: Report of a Family with Corticobasal Syndrome and a Literature Review","volume":"27","author":"Kojovic","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1212\/WNL.0b013e318234325e","article-title":"Teaching Neuroimages: Progressive Asymmetric Parkinsonism and Tendon Xanthomas","volume":"77","author":"Kirmi","year":"2011","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.62.9.1459","article-title":"Cerebrotendinous Xanthomatosis: Possible Higher Prevalence Than Previously Recognized","volume":"62","author":"Lorincz","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000506770","article-title":"Patients with Lately Diagnosed Cerebrotendinous Xanthomatosis","volume":"19","author":"Yunisova","year":"2019","journal-title":"Neurodegener. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/WNL.0000000000201112","article-title":"Long-Term Mri Findings in Patients with Cerebrotendinous Xanthomatosis Treated with Chenodeoxycholic Acid","volume":"99","author":"Stelten","year":"2022","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5334\/tohm.851","article-title":"Clinical and Imaging Profile of Patients with Cerebrotendinous Xanthomatosis\u2014A Video Case Series from India","volume":"14","author":"Katragadda","year":"2024","journal-title":"Tremor. Other Hyperkinet. Mov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2169\/internalmedicine1962.30.189","article-title":"Parkinsonism in Cerebrotendinous Xanthomatosis","volume":"30","author":"Fujiyama","year":"1991","journal-title":"Jpn. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jnnp.53.1.76","article-title":"Cerebrotendinous Xanthomatosis: Clinical and Mri Study (A Case Report)","volume":"53","author":"Fiorelli","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-510X(96)00011-1","article-title":"Pet Analysis of a Case of Cerebrotendinous Xanthomatosis Presenting Hemiparkinsonism","volume":"138","author":"Kuwabara","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-510X(00)00441-X","article-title":"Diphenylpyraline-Responsive Parkinsonism in Cerebrotendinous Xanthomatosis: Long-Term Follow up of Three Patients","volume":"182","author":"Ohno","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mdc3.12846","article-title":"Parkinsonism with Normal Dopaminergic Presynaptic Terminals in Cerebrotendinous Xanthomatosis","volume":"7","author":"Li","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/13554794.2023.2176777","article-title":"Clinical, Electrophysiological, and Genetic Characteristics of Cerebrotendinous Xanthomatosis in South Korea","volume":"28","author":"Kim","year":"2022","journal-title":"Neurocase"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11011-021-00714-7","article-title":"Patients with Cerebrotendinous Xanthomatosis Diagnosed with Diverse Multisystem Involvement","volume":"36","author":"Kisa","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1365-2133.2000.03318.x","article-title":"Cerebrotendinous Xanthomatosis: Report of a Case","volume":"142","author":"Nakamura","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/archderm.1986.01660230061011","article-title":"Capillary Gas Chromatography of Urine Samples in Diagnosing Cerebrotendinous Xanthomatosis","volume":"122","author":"Vermeer","year":"1986","journal-title":"Arch. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacl.2018.06.008","article-title":"Diagnosis, Treatment, and Clinical Outcomes in 43 Cases with Cerebrotendinous Xanthomatosis","volume":"12","author":"Duell","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e37976","DOI":"10.1097\/MD.0000000000037976","article-title":"Cerebrotendinous Xanthomatosis with Tremor as the Main Manifestation: A Case Report","volume":"103","author":"Zhao","year":"2024","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mdc3.12885","article-title":"The Levodopa Response Varies in Pathologically Confirmed Parkinson\u2019s Disease: A Systematic Review","volume":"7","author":"Pitz","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"109041","DOI":"10.1016\/j.ymgme.2025.109041","article-title":"Cerebrotendinous Xanthomatosis Occurs at High Frequency in Ashkenazi Jews","volume":"144","author":"Hanson","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymgme.2015.10.010","article-title":"Apparent Underdiagnosis of Cerebrotendinous Xanthomatosis Revealed by Analysis of ~60,000 Human Exomes","volume":"116","author":"Appadurai","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajmg.1320100209","article-title":"Genetics of Cerebrotendinous Xanthomatosis (Ctx): An Autosomal Recessive Trait with High Gene Frequency in Sephardim of Moroccan Origin","volume":"10","author":"Berginer","year":"1981","journal-title":"Am. J. Med. Genet."}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/17\/8\/117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:20Z","timestamp":1760033960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/17\/8\/117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["neurolint17080117"],"URL":"https:\/\/doi.org\/10.3390\/neurolint17080117","relation":{},"ISSN":["2035-8377"],"issn-type":[{"type":"electronic","value":"2035-8377"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}